A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD9742 After Multiple Doses Over 14 Days

AstraZeneca

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: Placebo; Drug: AZD9742

Study type: Interventional

Funder types: Industry

Identifiers

NCT01064388

D2690C00002

Details and patient eligibility

About

The purpose of this study is to determine the safety, tolerability and blood levels of AZD9742 after daily dosing for 14 days.

Enrollment: 36 patients

Sex: All

Ages: 23 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• BMI between 19-30

Exclusion criteria

• Positive Fecal Occult Blood Test
• Prescriptions that inhibit liver function
• Received flu/H1N1 vaccine within 2 weeks before first dose

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

36 participants in 2 patient groups, including a placebo group

1

Experimental group

Treatment:

Drug: AZD9742

2

Placebo Comparator group

Treatment:

Drug: Placebo